NASDAQ:BGNE - Beigene Stock Price, Forecast & News

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

Beigene Ltd (NASDAQ:BGNE) released its earnings results on Tuesday, November, 12th. The company reported ($5.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($3.56) by $1.55. The company earned $50.14 million during the quarter, compared to analyst estimates of $65.43 million. Beigene had a negative net margin of 192.75% and a negative return on equity of 53.11%. The company's revenue for the quarter was down 7.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.53) EPS. View Beigene's Earnings History.

Beigene is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Beigene.

10 brokerages have issued 1-year target prices for Beigene's shares. Their forecasts range from $165.00 to $230.00. On average, they anticipate Beigene's share price to reach $209.38 in the next year. This suggests a possible upside of 23.4% from the stock's current price. View Analyst Price Targets for Beigene.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene.

Media headlines about BGNE stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Beigene earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Beigene.

Some companies that are related to Beigene include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA) and Bausch Health Companies (BHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Crispr Therapeutics (CRSP), TENCENT HOLDING/ADR (TCEHY), Netflix (NFLX), Sarepta Therapeutics (SRPT), Canopy Growth (CGC), Gilead Sciences (GILD) and Roku (ROKU).

(BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Beigene's stock is owned by a number of of retail and institutional investors. Top institutional investors include Meag Munich Ergo Kapitalanlagegesellschaft MBH (0.04%), Rhenman & Partners Asset Management AB (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%) and IFM Investors Pty Ltd (0.00%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View Institutional Ownership Trends for Beigene.

BGNE stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd. Company insiders that have sold Beigene company stock in the last year include Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View Insider Buying and Selling for Beigene.

BGNE stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Meag Munich Ergo Kapitalanlagegesellschaft MBH and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Beigene.

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BGNE stock can currently be purchased for approximately $169.67.

Beigene has a market capitalization of $10.36 billion and generates $198.22 million in revenue each year. The company earns $-673,770,000.00 in net income (profit) each year or ($12.15) on an earnings per share basis. Beigene employs 2,070 workers across the globe.View Additional Information About Beigene.

The official website for Beigene is http://www.beigene.com/.

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]